Related content

Preclinical PK/PD modeling and human efficacious dose projection for a glucokinase activator in the treatment of diabetes

By Zager Michael   Kozminski Kirk   Pascual Bernadette   Ogilvie Kathleen   Sun Shaoxian  

Journal of Pharmacokinetics and Pharmacodynamics, Vol. 41, Iss. 2, 2014-04 ,pp. : 127-139

Springer Publishing Company

Access to resources Recommend Favorite

Human Hematopoietic Stem Cells in Gene Therapy: Pre-Clinical and Clinical Issues

By  

Current Gene Therapy, Vol. 8, Iss. 2, 2008-04 ,pp. : 135-146

Bentham Science Publishers

Access to resources Recommend Favorite

Oncolytic Adenovirus: Preclinical and Clinical Studies in Patients with Human Malignant Gliomas

By  

Current Gene Therapy, Vol. 9, Iss. 5, 2009-10 ,pp. : 422-427

Bentham Science Publishers

Access to resources Recommend Favorite

Model-based approaches to predict drug–drug interactions associated with hepatic uptake transporters: preclinical, clinical and beyond

By Barton Hugh A   Lai Yurong   Goosen Theunis C   Jones Hannah M   El-Kattan Ayman F   Gosset James R   Lin Jian   Varma Manthena V  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 9, Iss. 4, 2013-04 ,pp. : 459-472

Informa Healthcare

Access to resources Recommend Favorite

The failure of torcetrapib: is there a case for independent preclinical and clinical testing? – correspondence

By Shear Charles L  

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 14, 2008-10 ,pp. : 2561-2562

Informa Healthcare

Access to resources Recommend Favorite